Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
137 stopped studies mapped to Urinary Tract Carcinoma and descendants · 93% state a reason
Over the 137 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06290687 | Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative… | Phase 2 | withdrawn | Mar 4, 2024 | Case Comprehensive Cancer Center | PI left institution | Investigator |
| NCT04047693 | Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma | Phase 2 | terminated | Aug 7, 2019 | Pusan National University Yangsan Hospital | Poor accrual due to increased use of alternative neoadjuvant treatment options. | Enrollment / accrual |
| NCT05014139 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle… | Phase 1 | terminated | Aug 20, 2021 | Astellas Pharma Global Development, Inc. | Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility,… | Safety / toxicity |
| NCT07414992 | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With… | Phase 2 | withdrawn | Feb 17, 2026 | Memorial Sloan Kettering Cancer Center | The sponsor is no longer supporting the trial because they are no longer interested in studying the… | Other (stated, no rule matched) |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… | Phase 1 / Phase 2 | terminated | May 12, 2016 | National Cancer Institute (NCI) | Accrual and drug manufacturing and supply were discontinued in 2025. | Drug supply |
| NCT03869190 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and… | Phase 1 / Phase 2 | terminated | Mar 11, 2019 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk… | Other (stated, no rule matched) |
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | Phase 3 | terminated | Apr 8, 2014 | Abnoba Gmbh | The study was terminated because the required number of patients cannot be reached in the… | Safety / toxicity |
| NCT03324282 | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder…(GCISAVE) | Phase 2 | terminated | Oct 27, 2017 | University Hospital, Bordeaux | ANSM's refusal to validate ATU requests for avelumab in bladder cancer, Decrease in recruitment,… | Enrollment / accrual |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed… | Phase 3 | withdrawn | Apr 27, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in… | Phase 1 | terminated | Mar 13, 2012 | M.D. Anderson Cancer Center | \< 75 % participation | Other (stated, no rule matched) |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced… | Phase 1 / Phase 2 | terminated | May 26, 2021 | M.D. Anderson Cancer Center | PI requested. | Other (stated, no rule matched) |
| NCT05581589 | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial… | Phase 2 | terminated | Oct 14, 2022 | University of Washington | Study closed to accrual before meeting accrual goal due to major enrollment challenges based on the… | Enrollment / accrual |
| NCT05700227 | Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for…(ARTIA-Bladder) | N/A | terminated | Jan 26, 2023 | Varian, a Siemens Healthineers Company | Low enrollment | Enrollment / accrual |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | Phase 1 | terminated | May 17, 2023 | Aurigene Discovery Technologies Limited | Patient recruitment problems | Enrollment / accrual |
| NCT04856189 | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or… | Phase 1 / Phase 2 | terminated | Apr 23, 2021 | Mamta Parikh | Poor accrual. | Enrollment / accrual |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT04003610 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial… | Phase 2 | terminated | Jul 1, 2019 | Incyte Corporation | The reason this study was terminated was due to a business decision. There were no safety concerns… | Safety / toxicity |
| NCT04586244 | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or…(Optimus) | Phase 2 | terminated | Oct 14, 2020 | Incyte Corporation | Business Decision. No safety concerns contributed to this decision. | Safety / toxicity |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 3, 2022 | National Cancer Institute (NCI) | Feasibility issues | Other (stated, no rule matched) |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT01495676 | A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for…(GETUGV04) | N/A | terminated | Dec 20, 2011 | Institut du Cancer de Montpellier - Val d'Aurelle | not stated | Not stated |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT04887831 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer…(PRESERVE3) | Phase 2 | terminated | May 14, 2021 | G1 Therapeutics, Inc. | Sponsor no longer pursuing trilaciclib for the indication. | Other (stated, no rule matched) |
| NCT04936230 | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer | Phase 2 | terminated | Jun 23, 2021 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05248789 | OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer | Phase 2 | terminated | Feb 21, 2022 | Binhui Biopharmaceutical Co., Ltd. | Strategy adjustment | Sponsor / business decision |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05687721 | Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | Phase 1 / Phase 2 | withdrawn | Jan 18, 2023 | VA Office of Research and Development | The study drug is not available. | Other (stated, no rule matched) |
| NCT06421311 | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With…(URADJ) | — | terminated | May 20, 2024 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or… | Phase 1 | terminated | Feb 16, 2022 | Kinnate Biopharma | Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor… | Enrollment / accrual |
| NCT05819827 | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma… | — | terminated | Apr 19, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT02122172 | Afatinib in Advanced Refractory Urothelial Cancer | Phase 2 | terminated | Apr 24, 2014 | University of Chicago | Unable to meet accrual goal after several years | Enrollment / accrual |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | Phase 1 | withdrawn | Jul 11, 2023 | Orion Biotechnology Polska Sp. z o.o. | study terminated due to changes in the drug development plan | Other (stated, no rule matched) |
| NCT04322643 | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | Phase 2 | terminated | Mar 26, 2020 | Case Comprehensive Cancer Center | PI preference | Other (stated, no rule matched) |
| NCT03197571 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With… | Phase 1 / Phase 2 | withdrawn | Jun 23, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03272217 | Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial… | Phase 2 | terminated | Sep 5, 2017 | Arjun Balar, MD | Funder decision | Other (stated, no rule matched) |
| NCT04228042 | Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer | Phase 1 / Phase 2 | terminated | Jan 14, 2020 | M.D. Anderson Cancer Center | Drug manufacturer made the business decision to cease all infigratinib oncology research in the US… | Drug supply |
| NCT04871529 | Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and… | Phase 2 | terminated | May 4, 2021 | SWOG Cancer Research Network | inability to accrue sufficient patients | Enrollment / accrual |
| NCT04064190 | Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | Phase 2 | withdrawn | Aug 21, 2019 | MedPacto, Inc. | Changing trial strategy | Sponsor / business decision |
| NCT03486197 | Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced… | Phase 2 | terminated | Apr 3, 2018 | University of Washington | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT06424717 | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has… | Phase 2 | withdrawn | May 22, 2024 | EMD Serono Research & Development Institute, Inc. | Trial withdrawn based on re-prioritization of the clinical development path for tuvusertib. No… | Enrollment / accrual |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline… | Phase 2 | withdrawn | Oct 10, 2022 | AdventHealth | PI Decision based on no enrollment | Enrollment / accrual |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials